Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19339724 | 1.00 | TPSAB1 (0.44) | TPSAB1TPSD1TPSG1POLBL3MBTL1 | |
| SCHEMBL4759604 | 0.85 | SYK (0.41) | TPSAB1TPSD1TPSG1POLBL3MBTL1 | |
| SCHEMBL9977210 | 0.84 | ITGA4 (0.40) | HDAC3HDAC1HDAC2NCOR2SMN1; SMN2 | |
| SCHEMBL17656214 | 0.83 | MEN1 (0.38) | TPSAB1TPSD1TPSG1SMN1; SMN2 | |
| SCHEMBL2706217 | 0.83 | MEN1 (0.38) | TPSAB1TPSD1TPSG1SMN1; SMN2 | |
| SCHEMBL27963815 | 0.81 | CTSK (0.50) | L3MBTL1SYKMAPT | |
| SCHEMBL23760112 | 0.81 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1POLBL3MBTL1 | |
| SCHEMBL23760082 | 0.81 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1POLBL3MBTL1 | |
| SCHEMBL17369164 | 0.81 | SYK (0.46) | TPSAB1TPSD1TPSG1POLBL3MBTL1 | |
| SCHEMBL17369165 | 0.80 | TPSAB1 (0.45) | TPSAB1TPSD1TPSG1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | TPSAB1 4100/4885TPSD1 4219/4885TPSG1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.